MRNA cancer therapy takes aim at resistant blood cancers
NCT ID NCT07362732
First seen Jan 24, 2026 · Last updated May 22, 2026 · Updated 18 times
Summary
This early-stage study tests a new drug called WGb-0302 for people with blood cancers like multiple myeloma that have come back or stopped responding to other treatments. The drug uses mRNA technology (similar to some COVID-19 vaccines) to help the body target cancer cells. About 20 adults aged 18-75 will take part to check safety and find the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.